Cowen Upgrades UNH and HUM Stocks to Buy and Lifts Price Targets After Healthcare Sell-Off. Here’s Why

Cowen upgraded UnitedHealth (UNH) and Humana (HUM) to Buy, citing strong earnings growth prospects. Analyst Ryan Langston raised UNH's price target to $455 and HUM's to $485. Both stocks rose in pre-market trading after a healthcare sector sell-off due to proposed CMS regulations. Cowen expects UNH's EPS to grow mid-high teens through 2028 and HUM's to reach $40.42 by 2028.

Original reporting
Published Nov 20, 2026, 12:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 1:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$UNH
Bullish
high confidence
Mentioned
$UNH · $HUM
Relevance
7/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$UNHBullishMed
01

Why it matters

The upgrades provide a short‑term catalyst that could reverse the recent sector weakness.

02

Market read

Analyst upgrades for two large‑cap insurers may spark a sector‑wide rebound after a regulatory‑driven pullback.

03

What to watch

Potential regulatory headwinds and the timing of CMS rule finalization may temper upside.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Recent sell‑off in health‑care stocks after a proposed CMS audit rule, with analysts now finding upside in the sector.

Company-level read

Ticker impact

$UNHBullishHigh confidence
Context

Cowen upgraded UnitedHealth to Buy and raised its price target to $455, citing strong earnings growth prospects.

Expected impact

upward pressure as traders price in the upgrade and higher target

Evidence & confidence

Analyst upgrade with a 13% target increase is a fresh catalyst for a large‑cap insurer.

$HUMBullishHigh confidence
Context

Cowen upgraded Humana to Buy and lifted its price target to $485, highlighting stronger Medicare Advantage outlook.

Expected impact

upward pressure as market absorbs the new buy rating and target

Evidence & confidence

Similar to UNH, the fresh upgrade and sizable target raise provide a clear short‑term upside catalyst.

Market effects

Healthcare insurance sector may see broader rally as analysts upgrade major players.

U.S. equity markets could see modest gains in health‑care indices.

Limited to U.S. markets; no immediate global spillover.

Counterpoint

If the CMS CRUSH rule materializes, it could pressure margins despite the upgrade.

Key entities

  • Cowen

    Provided the upgrades and new price targets for UNH and HUM.

  • CMS

    Proposed the CRUSH rule that initially triggered the sector sell‑off.

Related articles

$UNHMed

UnitedHealth Stock (UNH) Rises After the Healthcare Company Filed a Lawsuit Against the U.S. Government

UnitedHealth (UNH) stock rose 4.61% after filing a lawsuit against the U.S. government over a star rating drop by the Centers for Medicare & Medicaid Services, claiming improper measures were used. The company seeks higher ratings for 45 contracts, potentially increasing them by 0.5 to 1.5 stars. Analyst Ryan Langston upgraded UNH to Buy with a $455 price target, citing strong earnings growth.

$UNHMed

UnitedHealth sues US government over lowered Medicare Advantage star ratings

UnitedHealth Group sued the US government over its 2027 Medicare Advantage star ratings, claiming improper calculations could reduce bonus payments and patient benefits. The company, the largest Medicare Advantage insurer, said ratings for 45 contracts would rise if calculated correctly. CMS declined to comment. Other insurers, including CVS Health, have also sued over their ratings.

$UNHMed

UnitedHealth sues to reverse downgraded Medicare Advantage quality scores

UnitedHealth Group sued the U.S. government over lowered Medicare Advantage star ratings for 2027, joining 14 other insurers. The company, the largest Medicare Advantage insurer, claims the ratings calculation is inconsistent and unfairly reduces scores below bonus thresholds. Medicare Advantage plans are rated on a scale of one to five stars, with higher ratings earning bonus payments.